Latham & Watkins Advises Initial Purchasers in Haemonetics’ US$435 Million Convertible Notes Offering

Haemonetics Corporation (NYSE: HAE) has announced the pricing of its offering of US$435 million aggregate principal amount of 0% Convertible Senior Notes due 2026 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The offering size was increased from the previously announced offering size of US$425 million aggregate principal amount of notes.

Latham & Watkins LLP represented the initial purchasers in the offering with a capital markets team led by Boston/New York partner Wesley Holmes and New York partner Reza Mojtabaee-Zamani, with New York associates Eric Rice, Marc Langer, Kate Kim, and Paul Rafla. Advice was also provided on tax matters by New York partner Elena Romanova, with New York associate Michael Syku.